TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

GlobeNewswire Inc. Logo GlobeNewswire Inc. By 4D Molecular Therapeutics
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.

Insights
V   positive

Benefiting from digital payment trends, strong network effects, potential to become a trillion-dollar company, and ability to adapt to potential economic challenges like inflation


FDMT   positive

Secured significant upfront payment, potential milestone payments, and strategic partnership expanding global reach of their therapeutic candidate